Guidance

1.1
Febuxostat, within its marketing authorisation, is recommended as an option for the management of chronic hyperuricaemia in gout only for people who are intolerant of allopurinol (as defined in section 1.2) or for whom allopurinol is contraindicated.
1.2 For the purposes of this guidance, intolerance of allopurinol is defined as adverse effects that are sufficiently severe to warrant its discontinuation, or to prevent full dose escalation for optimal effectiveness as appropriate within its marketing authorisation.
1.3
People currently receiving febuxostat should have the option to continue therapy until they and their clinicians consider it appropriate to stop.
Febuxostat for the management of hyperuricaemia in people with gout NICE technology appraisal guidance 164 2 The technology 2.1 Febuxostat (Adenuric, Ipsen) is a non-purine selective inhibitor of xanthine oxidase that achieves its therapeutic effects by decreasing the serum uric acid concentration. Febuxostat has a marketing authorisation for the treatment of chronic hyperuricaemia in conditions where urate/uric acid deposition has already occurred (including a history or the presence of tophi and/or gouty arthritis).
2.2
The most common side effects associated with febuxostat are diarrhoea, nausea, headache, liver function test abnormalities and rash. Uncommon side effects include fatigue, oedema, dizziness, altered sense of taste, increase in blood amylase, decrease in platelet count, increase in blood creatinine, and arthralgia. Rare side effects include nervousness, insomnia, asthenia and renal insufficiency. The summary of product characteristics (SPC) states that treatment with febuxostat is not recommended for people with ischaemic heart disease or congestive heart failure. For full details of side effects and contraindications, see the SPC.
2.3
The recommended dose of febuxostat is 80 mg once daily. If the person's serum uric acid concentration is above 6 mg/100 ml (360 µmol/litre) after 2-4 weeks of treatment with 80 mg once daily, febuxostat 120 mg once daily may be considered. The price for febuxostat 80 mg and 120 mg is £0.87 per tablet. Annual treatment costs are approximately £318. Costs may vary in different settings because of negotiated procurement discounts.
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The manufacturer's submission
The Appraisal Committee (appendix A) considered evidence submitted by the manufacturer of febuxostat and a review of this submission by the Evidence Review Group (ERG; appendix B).
3.1
The manufacturer's decision problem specified febuxostat (80 mg or 120 mg once daily) as the intervention of interest in a population of adults with hyperuricaemia in gout. The comparator specified by the manufacturer was fixed-dose allopurinol (300 mg once daily). The manufacturer did not present comparisons with alternative comparators such as sulphinpyrazone, benzbromarone, probenecid or combinations of these treatments. The health outcomes considered included serum uric acid concentration, gout flare rates, reduction in size of tophi, and health-related quality of life. The results of the economic evaluation were expressed as incremental cost per quality-adjusted life year (QALY) over a time horizon of 2 years.
3.2
The manufacturer presented evidence on the clinical effectiveness of febuxostat from three randomised controlled trials (RCTs): the FACT trial, the APEX trial and the TMX-00-004 study. The FACT trial was a 52-week, phase III, multi-arm, randomised, double-blind, parallel-group trial that compared febuxostat 80 mg/day (n = 257), febuxostat 120 mg/day (n = 251) and allopurinol 300 mg/day (n = 254). The APEX trial was a 28-week, phase III, multi-arm, randomised, double-blind trial that compared febuxostat 80 mg/day (n = 267), febuxostat 120 mg/day (n = 269), febuxostat 240 mg/day (n = 134), allopurinol 300 or 100 mg/day (n = 268) and placebo (n = 134). The reduced dose of allopurinol (100 mg/day) in the APEX trial was used for 10 patients with renal impairment. In the APEX and FACT trials, colchicine and naproxen (a non-steroidal anti-inflammatory drug [NSAID]) were given as prophylaxis for treatment-initiated gout flares during the first 8 weeks of treatment. The TMX-00-004 study was a 4-week, phase II (dose-response), multicentre, randomised, double-blind, parallel-group trial that compared febuxostat 40 mg/ day (n = 37), febuxostat 80 mg/day (n = 40), febuxostat 120 mg/day (n = 38) and placebo (n = 38).
3.3
Supplementary data in support of the clinical effectiveness of febuxostat were provided by the manufacturer from two open-label extension studies. The 
3.5
The manufacturer's pooled analysis suggested that febuxostat 80 mg/day and 120 mg/day was significantly more effective (p ≤ 0.05) than fixed-dose allopurinol (300 or 100 mg/day) at lowering the serum uric acid concentration to target therapeutic levels (of below 6 mg/100 ml) at the last three visits and at the final visit. Febuxostat at either dose was also significantly more effective (p ≤ 0.05) than fixed-dose allopurinol (300 mg/day) at lowering the serum uric acid concentration from baseline levels at the final visit. No statistically significant differences were observed with febuxostat 80 mg/day compared with allopurinol (300 or 100 mg/day) in the proportion of patients requiring treatment for gout flares. In contrast, the proportion of patients requiring treatment for gout flares was statistically significantly higher (p ≤ 0.05) with febuxostat 120 mg/day than with allopurinol (300 or 100 mg/day), both during (weeks 1-8) and after (weeks 9-52) prophylaxis. The difference was more marked during the initial weeks of treatment. No statistically significant differences were found between groups in the percentage reduction in tophus area except at week 28, when statistically significantly greater reductions in primary tophus size from baseline were observed with febuxostat 120 mg/day than with allopurinol.
3.6
Post-hoc subgroup analysis of the pooled data showed that febuxostat was more effective (p ≤ 0.05) than allopurinol in lowering serum uric acid concentration to below 6 mg/100 ml in three subgroups of patients defined according to baseline serum acid concentrations of below 9 mg/100 ml, between 9 and 10 mg/100 ml and above 10 mg/100 ml. The proportion of patients whose serum uric acid concentration fell below the target level of 5 mg/100 ml was higher (p ≤ 0.05) among those receiving febuxostat than among those receiving fixed-dose allopurinol. No subgroup analyses were conducted for patients with renal impairment or those whose condition did not respond to allopurinol.
3.7
Results from the EXCEL extension study showed that a higher proportion of patients receiving febuxostat (80 mg/day or 120 mg/day) remained on initial treatment than among those receiving fixed-dose allopurinol (300 or 100 mg/ day) after more than 24 months of follow-up. For each year of febuxostat treatment in the EXCEL trial, the number of gout flares decreased over time.
However, the ERG considered that this evidence should be treated with caution, since statistical comparisons between treatment groups were not reported. In addition, no data were provided on withdrawals because of gout flares, adverse events or lack of response to treatment.
3.8
The ERG considered that the evidence presented in support of the clinical effectiveness of febuxostat in comparison with allopurinol may not be adequate. This is because guidelines for gout management from the British Society of Rheumatology and British Health Professionals in Rheumatology (BSR guidelines) and the European League Against Rheumatism (EULAR guidelines), and the SPC for allopurinol, recommend dose titration for allopurinol according to therapeutic targets. It is possible that dose-titrated allopurinol may be more effective than fixed-dose allopurinol, and that the additional clinical benefits of febuxostat may not be as great in routine practice as is suggested by the results from the RCT comparisons with fixed-dose allopurinol. However, the ERG noted that dose titration of allopurinol is rarely carried out in routine clinical practice.
3.9
The ERG expressed concerns about the analysis of clinical efficacy based on pooling data across trials, because this approach fails to preserve Febuxostat for the management of hyperuricaemia in people with gout NICE technology appraisal guidance 164 randomisation in the RCT evidence, which may introduce bias. The ERG carried out a corrected meta-analysis (based on both fixed-and random-effects modelling) using the RCT data and evidence presented by the manufacturer. The results of the meta-analysis showed that the probability of reaching therapeutic targets for serum uric acid concentration was statistically significantly higher for patients receiving febuxostat (80 or 120 mg/day) than for those receiving fixed-dose allopurinol (300 mg/day). The ERG's metaanalysis also showed that a higher proportion of patients receiving febuxostat needed treatment for gout flares (both during prophylaxis [weeks 1-8] and after prophylaxis [weeks 9-52]) compared with those receiving fixed-dose allopurinol. For the febuxostat 80 mg/day group this difference was not statistically significant (p > 0.18), but for the 120 mg/day febuxostat group it was (p < 0.05).
3.10
The £6281 to £239,928 per QALY). The cost-effectiveness acceptability curve reported that the probability that febuxostat 80 mg/day (titrated to 120 mg/day where appropriate) had an ICER lower than £20,000 per QALY gained compared with fixed-dose allopurinol was 63%.
3.12
The manufacturer presented a number of univariate sensitivity analyses to evaluate the impact of changing the following variables: the time horizon of the model; the protective effect of colchicine prophylaxis; discount rates; the assumed cost of febuxostat; the disutility associated with increments in serum uric acid concentration; and the proportion of patients with a serum uric acid concentration below 360 µmol/litre (6 mg/100 ml) between 4 and 24 months of treatment with febuxostat. The results of these sensitivity analyses showed that the key drivers of the economic model were: (1) 
3.13
The ERG noted a number of areas of uncertainty around the cost-effectiveness analyses undertaken in the manufacturer's submission. The ERG noted that the natural history of people with hyperuricaemia in gout who did not receive treatment was not modelled, and hence no inference could be made of the cost effectiveness of febuxostat compared with no treatment. The ERG requested that a sequence of strategies where patients progress to an Febuxostat for the management of hyperuricaemia in people with gout NICE technology appraisal guidance 164 alternative intervention (allopurinol, febuxostat or no treatment) following lack of response should be evaluated. The manufacturer declined the request, arguing that estimation of a sequential strategy was not feasible because of a lack of clinical data. In addition, the manufacturer argued that it was unethical to consider febuxostat as second-line therapy when it is cost effective as firstline therapy, and that the only appropriate comparison was that investigated in the pivotal RCTs; that is, first-line therapy. The ERG asserted that appropriate modelling assumptions could have been made to allow some exploratory analysis.
3.14 The ERG noted that no data were provided on the likely serum uric acid concentrations of patients who receive no treatment, and that the model assumes full treatment adherence and usage over the time horizon modelled.
However, evidence from the FACT and APEX trials showed that treatment continuation rates were lower for febuxostat than for allopurinol. Contradictory
evidence from the open-label EXCEL trial reports gave treatment continuation rates of 35% for 80 mg/day febuxostat and 10% for 120 mg/day febuxostat, but only 5% for allopurinol. Additional evidence presented by the manufacturer suggested that in a randomised subset of the EXCEL trial, 76% of patients receiving 80 mg/day febuxostat, 71% of patients receiving 120 mg/day febuxostat and 40% of patients receiving allopurinol remained on initial treatment after more than 24 months. The ERG stated that the lack of data on the likely serum uric acid concentrations of patients who receive no treatment made it difficult to accurately account for treatment discontinuation rates in the manufacturer's economic model. An assumption of full treatment adherence and usage over the time horizon could potentially bias the results of the economic analysis in favour of febuxostat.
3.15
The ERG noted that in the manufacturer's economic model, data on the number of gout flares within the initial 3 months of treatment were taken from the pooled analysis of the results from the APEX and FACT trials. The flare rates were reduced by 78% by assuming that patients received 3 months of colchicine prophylaxis. However, this reduction may be an overestimate, since in the APEX and FACT trials colchicine prophylaxis was given for only 8 weeks. After the first 3 months of treatment, the proportion of gout flares was assumed to be related to serum uric acid concentration, on the basis of a The ERG stated that a relationship, not necessarily linear, between serum uric acid concentration and number of gout flares may still be found with more appropriate analysis and larger or different datasets.
3.16
The persuaded that these options need not be considered as routine or bestpractice comparators.
4.3
The Committee discussed the possible use of febuxostat as an alternative to allopurinol as first-line therapy; that is, where allopurinol is tolerated and not contraindicated. It identified that it has been established in clinical practice (as set out in BSR and EULAR guidelines) that allopurinol is most effective when given in a titrated regimen depending on the serum uric acid concentration.
The Committee heard that even though many GPs limit their prescribing of allopurinol to a fixed dose of 300 mg/day, this is not best practice, particularly in the subset of people with gout for whom febuxostat might be considered.
The Committee concluded that up-titrated allopurinol (to a maximum of 900 mg/day) should be considered as the best-practice comparator for febuxostat.
4.4
The Committee also discussed the outcome measures used. In particular, it discussed the surrogate outcome of serum uric acid concentration. It heard from the clinical specialists that a significant proportion of the population have a high serum uric acid concentration, but that comparatively few people present with clinical symptoms related to gout. However, although it noted that there remained some uncertainty about the relationship between serum uric acid concentration and clinical benefits (such as gout flare control, renal impairment and reduction in tophi size and number), the Committee was persuaded that a reduction in the serum uric acid concentration below the 'saturation point' (approximately 6 mg/100 ml) was necessary to avoid precipitation of uric acid crystals in tissues in the long term. Additionally, although the association between serum uric acid concentration and symptoms of gout is complex and not completely understood, the Committee concluded that it was reasonable to assume that a relationship with symptoms is likely above a serum uric acid concentration of 6 mg/100 ml.
4.5
The Committee discussed the evidence for the clinical effectiveness of febuxostat, and specifically the RCTs and extension studies in which febuxostat was compared with fixed-dose allopurinol. It noted the ERG critique of the efficacy results from the pooled analysis of data from the APEX and FACT trials and agreed that the approach was methodologically inappropriate, in that it failed to preserve randomisation in the RCT evidence. The Committee noted that the manufacturer was asked to conduct a meta-analysis of the RCT data but this was not provided. The Committee noted, however, that an appropriately conducted meta-analysis from the ERG showed very similar results, demonstrating that febuxostat is more effective than allopurinol in lowering serum uric acid concentration.
4.6
The Committee noted that in the main comparative trials, fixed-dose allopurinol was found to effectively reduce the serum uric acid concentration below the saturation point of 6 mg/100 ml in a substantial proportion of patients. The
Committee accepted that febuxostat is more effective at reducing serum uric acid concentration than fixed-dose allopurinol. The Committee also agreed that it was plausible that a reduction in serum uric acid concentration was associated with a reduction in gout symptoms, However, it concluded that the benefits of febuxostat compared with allopurinol (using a fully titrated dosing Febuxostat for the management of hyperuricaemia in people with gout NICE technology appraisal guidance 164 schedule) in improving clinical outcomes, such as gout flare control, reduction in tophi size and number, and avoidance of joint and organ damage as a result of urate deposition in the longer term, had not been clearly demonstrated.
4.7
The Committee discussed the observation that the proportion of people with recurrent gout flares needing treatment was higher in the febuxostat arm than in the allopurinol arm of the APEX and FACT RCTs, although the number of gout flares declined over time. It heard from the clinical specialists that this phenomenon is seen with all uric acid-lowering therapies. Although the mechanism is not completely understood, it is believed to relate to the rate of change in serum uric acid concentration, with treatments that reduce serum uric acid concentration more effectively and rapidly having a more pronounced effect. The Committee accepted this explanation and noted that an initial rise in clinical gout flares can be mitigated with the use of prophylaxis with an NSAID or colchicine. Nevertheless, it concluded that, where they remain, these initial flares are of clinical importance.
4.8
The Committee considered the adverse effects associated with febuxostat in comparison with fixed-dose allopurinol. In particular, it noted that there were a higher number of cardiovascular events and deaths across the febuxostat arms of the APEX, FACT and EXCEL studies. It noted that the manufacturer had reported such differences as not being statistically significant, but that the ERG had found a lack of completeness in reporting, despite requests for clarification. However, it was noted that no dose-response relationship between these events and increasing doses of febuxostat had been observed in RCTs. The Committee also noted that the marketing authorisation for febuxostat carries special warnings and precautions that preclude its use in patients with ischaemic heart disease or congestive heart failure.
4.9
The Committee discussed the economic model presented by the manufacturer, initially covering only the use of febuxostat as an alternative to first-line allopurinol therapy, and the ERG's subsequent critique. It had a number of concerns about the model structure and parameter assumptions in the model.
The Committee was concerned that the evidence base was incomplete because the comparison presented by the manufacturer was limited to a suboptimal (that is, fixed-dose) regimen of allopurinol. The manufacturer did Febuxostat for the management of hyperuricaemia in people with gout NICE technology appraisal guidance 164 not consider that it could include up-titrated allopurinol as a comparator in the current model. The Committee concluded that the manufacturer's ICER calculation for febuxostat compared with fixed-dose allopurinol, having failed to consider up-titrated allopurinol, was a substantial underestimate.
4.10
The Committee heard from clinical specialists that new and relatively unfamiliar drugs are often used, initially at least, when current drugs are inappropriate or have failed to achieve a response. It understood that this was the case for febuxostat, and that its place in the pathway of care was preferentially as second-line treatment after allopurinol. It was mindful that the ERG had requested modelling of sequential use when patients progress to the need for alternative treatments (following lack of response to allopurinol treatment) or no-treatment options, and that the manufacturer had declined the request on the basis of lack of evidence. The Committee noted that these shortcomings of the manufacturer's model were too great for the ERG to be able to rectify and offer an alternative ICER. It also noted that the manufacturer had subsequently offered to model sequential treatment strategies, but that it estimated that this would take between 4 and 6 months.
4.11
The Committee discussed the relationship assumed in the manufacturer's model between serum uric acid concentration, frequency of gout flares and how this may translate into improvements in long-term health-related quality of life. The Committee noted clarification from the manufacturer that the estimated relationship was non-linear. The Committee considered the ERG's concerns about the validity of the 'multivariate analysis' from which this assumption was derived. It noted the ERG's critique that this was based on a dataset from which some data points had been selectively excluded. The Committee also considered the statements from the clinical specialists that although a relationship between serum uric acid concentration above the saturation point and both frequency of gout flares and long-term adverse outcomes of gout is plausible, the strength and nature of the relationship is not clearly understood. The Committee concluded that there remained some uncertainty about the relationship between absolute serum uric acid concentration and gout symptoms in general, and that this was an additional source of uncertainty in the estimation of the incremental QALYs gained.
4.12
The Committee discussed the exploratory analysis by the ERG of the incremental QALY gain associated with the effect of lowering the serum uric acid concentration. The overall incremental QALY gain (0.032) included both the incremental QALY gain from the avoidance of gout flares and the 'chronic utility gain' from the prevention of gout-related symptoms. This is much higher than the overall incremental QALY gain ( only a partial treatment effect was achieved, potentially biased the results of the economic analysis in favour of febuxostat. It was, however, mindful of conflicting evidence from the EXCEL trial that patients on febuxostat were more likely to continue treatment. It also noted that there could potentially be long-term benefits associated with febuxostat, such as avoidance of adverse renal events in comparison with other therapies. The Committee considered the univariate sensitivity analysis, which showed that an extension of the manufacturer's economic model to 5 years had a marginal impact on the basecase ICER. However, it noted that this simply reflects the assumption that patients continue to accrue treatment benefits beyond the 2-year time horizon.
4.16
The Committee discussed cost assumptions in the model. It considered it plausible that the main drivers of incremental cost would be the drug cost (noting the 13-fold difference in cost between febuxostat and allopurinol), and the costs saved by avoiding treatment costs associated with any gout flares. It concluded that the total cost avoided by reduction in flares may have been overstated because the difference in expected number of flares may have Febuxostat for the management of hyperuricaemia in people with gout NICE technology appraisal guidance 164 been overestimated, as discussed above (although this may be offset by the cost savings from the long-term benefits of alleviating gout symptoms).
4.17
The Committee discussed the results of a second economic analysis presented by the manufacturer showing that a comparison between febuxostat and a no-treatment (placebo) option gave an ICER of £3727 per QALY gained over a 2-year time horizon. It considered that this estimate was also subject to substantial uncertainty, given the concerns discussed above regarding the approach taken by the manufacturer in the economic analysis. The Committee considered, however, that given that the option of titrated allopurinol was obviously not available for the treatment of people who are intolerant of allopurinol or for whom allopurinol is contraindicated, the ICER of febuxostat in these groups of patients was very likely to be at an acceptable level, despite the degree of uncertainty because of lack of evidence.
4.18
The Committee further discussed the use of febuxostat in cases where treatment goals were not achieved with allopurinol. The Committee considered that there is no evidence, and no basic pharmacodynamic reason, to suppose that febuxostat would confer any benefit for patients in whom up-titrated allopurinol has failed to lower the serum uric acid concentration below the 'saturation point'. Thus the Committee considered that febuxostat could be recommended as a treatment option in people with chronic hyperuricaemia and symptomatic gout who are intolerant of allopurinol (defined as adverse effects that are sufficiently severe to warrant its discontinuation, or to prevent full dose escalation for optimal effectiveness as appropriate within its marketing authorisation), or for whom allopurinol is contraindicated (for instance in cases of severe renal impairment or interactions with other medications).
4.19
Overall, the Committee concluded that although febuxostat had been shown to be more effective than fixed-dose allopurinol in lowering serum uric acid 
5.3
When NICE recommends a treatment 'as an option', the NHS must make sure it is available within the period set out in the paragraph above. This means that, if the doctor responsible for the care of someone with gout thinks that febuxostat is the right treatment for the management of hyperuricaemia, it should be available for use, in line with NICE's recommendations.
5.4
NICE has developed tools to help organisations implement this guidance (listed below).
Costing report and costing template to estimate the savings and costs associated with implementation.
Audit support for monitoring local practice.
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